Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

cs. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or future clinical trials. In addition, results may be affected by the failure to enter into new collaborations on any of its research and development programs in the event that the merger transaction is not consummated, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, the scope and validity of patent protection for its products, and its ability to obtain additional funding to support its operations. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2007 and the Company's most recent quarterly report on Form 10-Q as well as subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances af
'/>"/>
SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Pa. , July 25, 2014 /PRNewswire-iReach/ -- ... and consulting for global corporations operating in highly ... host its first annual Global User Group Conference, ... historic Philadelphia, Pennsylvania at ... - http://photos.prnewswire.com/prnh/20140724/130263 This ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
(Date:7/24/2014)... Calif. , July 24, 2014  Now available ... to home. Rehealth Regenerative Therapies , located in ... and other physically active people a new health option: ... Regardless of age, countless patients suffer from joint ... activities, such as muscle tears, torn rotator cuff, tennis ...
(Date:7/24/2014)... Security forces worldwide rely on sophisticated equipment, trained ... other public areas against terrorist attacks. A revolutionary ... about to make their job much easier. , ... Patolsky of Tel Aviv University ,s School of ... developed by the Herzliya company Tracense, picks up ...
Breaking Biology Technology:Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... February 26 Arpida Ltd.,(SWX: ARPN) today reported that ... intravenous iclaprim in its first indication,complicated Skin and Skin ... weeks., Arpida has agreed with the U.S. Food ... rolling process. Using a ,rolling NDA, allows modules,within the ...
... using Star-P, WALTHAM, Mass., Feb. 26 ... Research Lab (NUCAR) and the National,Science Foundation,s ... (CenSSIS) are teaming with Massachusetts General Hospital ... technology that improves breast,cancer screening accuracy. The ...
... Talent Management Vendor,s Model ... Market, OTTAWA, Feb. 26 /PRNewswire/ - Halogen Software ... management software,today announced that FactPoint Group has profiled Halogen ... market. The Silicon Valley based research and,consulting firm selected ...
Cached Biology Technology:Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 2Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 3Northeastern University and Mass General Hospital Increase the Accuracy, While Reducing the Diagnosis Time, for Breast Cancer Detection 2Northeastern University and Mass General Hospital Increase the Accuracy, While Reducing the Diagnosis Time, for Breast Cancer Detection 3FactPoint Group Recognizes Halogen for "On-Choice" Deployment Model 2
(Date:7/24/2014)... has different effects on different species of fish, ... of Bristol and Exeter which tested fish anti-predator ... a flying seagull predator model when exposed to ... European minnows. , Lead author Dr Irene ... "Noise levels in many aquatic environments have increased ...
(Date:7/24/2014)... 2014 Some sticky research out of York University ... certain species of toxic grass fungus: moose saliva (yes ... Biology Letters , "Ungulate saliva inhibits a grassendophyte mutualism" ... red fescue grass (which hosts a fungus called epichlo ... fungus growth and less toxicity. , "Plants have evolved ...
(Date:7/24/2014)... Bhavani Iyer, O.D., a low vision specialist at The ... Medical School, has been awarded a grant to help ... with eyeglasses, medication or surgery. , Even with corrective ... at best. However, there are a variety of low ... to help offset their vision loss. , Iyer is ...
Breaking Biology News(10 mins):Moose drool inhibits growth of toxic fungus: York U research 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2
... of native North Americans offers new insights into the migration ... home in northwest North America to the southwestern United States. ... to have occurred about 500 years ago. The ... detailed this month in the American Journal of Physical ...
... literature review conducted by a team of researchers from ... and the Connecticut Center for Eliminating Health Disparities among ... and health outcomes among Latinos living in the United ... the Journal of Nutrition Education and Behavior, ...
... spotting the cuckoo in the nest. But if you don,t, ... hosts distinguish impostor eggs from their own has long puzzled ... through our own eyes. It was only when people started ... how hosts recognise a cuckoo egg in the nest. Marcel ...
Cached Biology News:Y chromosome study sheds light on Athapaskan migration to southwest US 2Y chromosome study sheds light on Athapaskan migration to southwest US 3Peers important for nutrition education among Latinos 2How birds spot the cuckoo in the nest 2
Screening assay to detect the Listeria monocytogenes in food samples by,DNA amplification and molecular hybridization on a microtiter plate....
... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
... PCR Enhancer (with betaine) substantially improves ... and specificity for amplification of many ... in PCR eliminates the base-pair composition ... thermal stability, suppresses pauses of DNA ...
... Systems provide rapid, precise localization of ... frozen or paraffin-embedded tissue, cytospins and ... facilitate double or triple labeleing experiments, ... with primary antibodies of different animal ...
Biology Products: